About this trial
This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.
Eligibility criteria
Qualifiers
At least one stone ≥ 1.2cm
Scheduled to undergo planned PCNL
Age ≥ 18 years
Disqualifiers
Unable to provide informed consent
Pre-existing nephrostomy tube
Multi access cases
Stone in calyceal diverticulum/hydrocalyx
Trial design
Treatments tested in this trial
- Floseal
- Surgicel
- Surgiflo
- Balloon Tamponade